Four-Year Follow-Up for kidney rejection drug shows promise
NCT ID NCT07444489
Summary
This study follows kidney transplant patients who developed antibody-mediated rejection (where the body attacks the new kidney) after participating in an earlier felzartamab trial. Participants can receive the drug for up to four more years to help control the rejection. Researchers will monitor long-term safety, kidney health through biopsies, and how well the treatment continues to work over time.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTIBODY-MEDIATED REJECTION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.